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Abstract
Objective—Antenatal corticosteroids (ACS) decrease respiratory distress syndrome in singleton
gestations. Twin data is less clear. Obesity and BMI also affect medication distribution volume.
We evaluated whether maternal or neonatal cord betamethasone concentrations differed in twin
gestations or in obese patients.
Study Design—Participants receiving betamethasone in a randomized controlled trial of weekly
ACS were identified. We analyzed maternal delivery and cord serum betamethasone
concentrations comparing singletons with twins and obese (BMI≥30) with non-obese women.
Results—55 maternal and 45 cord blood samples were available. Unadjusted median maternal
serum concentrations appeared paradoxically higher in both twin gestations and the obese.
However, after controlling for confounders, there were no differences in betamethasone
concentrations in maternal serum or cord blood between singletons and twins (p=0.61 v. p=0.14)
or non-obese and obese women (p=0.67 v. 0.12).
Conclusion—Maternal and umbilical cord blood serum betamethasone concentrations are not
different in twin gestations or obese women.
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INTRODUCTION
Antenatal corticosteroids are administered to promote fetal pulmonary maturity in
pregnancies at risk for preterm delivery between 24 and 34 weeks’ gestation. However, the
dosing requirements in women with multiple gestations and maternal obesity have not been
evaluated. Liggins and Howie[1] described a dose of 12 mg of betamethasone given twice,
24 hours apart, in their seminal paper introducing this treatment. Although this regimen was
chosen arbitrarily, it is the same regimen that many practitioners continue to use today, and
is endorsed by the American College of Obstetricians and Gynecologists [2] and the NIH
Consensus Statement on antenatal corticosteroids [3].
Body composition, blood flow, and binding of plasma proteins are the principal factors that
affect the volume of distribution of medication.[4] During pregnancy blood volume
increases by 40–45% on average, and greater increases are noted in twin gestations.[5] This
increased blood volume along with the decrease in oncotic pressure found in pregnancy, can
alter the volume of distribution of certain medications administered during pregnancy.
Antenatal corticosteroids have not reliably been shown to decrease the rate of RDS in twin
gestations.[6] It has been hypothesized that the more pronounced physiologic changes in
twins compared to singletons may account for this observation.[7]
Similarly, obesity can affect the volume of distribution of medication. An intramuscular
injection of betamethasone soluspan contains both betamethasone phosphate, a short-acting,
rapidly absorbed compound, and betamethasone acetate, a longer-acting compound with
delayed absorption. The drug is then metabolized primarily in the liver, but also in the
kidney and surrounding tissue. Blood flow per gram of fat in normal weight individuals is
more than blood flow in the morbidly obese,[8] and blood flow influences the volume of
distribution. Although obesity does not seem to affect absorption, tissue distribution and
drug elimination are changed. This raises concerns as to whether the same concentration of
betamethasone is available to the fetus of an obese mother as compared to one that is normal
weight. Therefore, we chose to study whether the number of fetuses (singleton or twin) or
maternal obesity affects the concentration of betamethasone in maternal serum or fetal cord
blood.
MATERIALS AND METHODS
This is an analysis of biological fluids collected within a randomized, double-blinded,
placebo-controlled clinical trial conducted by the Eunice Kennedy Shriver National Institute
of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units
(MFMU) Network that evaluated whether weekly injections of betamethasone decreased
neonatal respiratory morbidity. Full details of the methods and study design have been
previously reported.[9] All participants received one course of betamethasone prior to
randomization. As part of the original study, maternal serum was collected at randomization
and at delivery. Cord blood was also collected at delivery. These samples were centrifuged
and frozen at −80° C for future analysis. The present analysis was confined to participants
continuing to receive weekly betamethasone injections who delivered within one week of
steroid administration.
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All serum samples were analyzed in a single batch at Anapharm Inc (Québec, Canada).
Determinations of betamethasone (Celestone ®) concentrations were made using high
performance liquid chromatography with tandem mass spectrometry detection using an
assay developed by Anaphram Inc. Specifically, the biological matrix used for the assay
included human plasma (with EDTA) in which betamethasone was measured over a
concentration range of 0.5 to 50 ng/mL. This method has sensitivity demonstrated at the
lower limit of quantitation (0.500 ng/mL). The quality control (QC) samples measured
betametasone at four levels, and they were within ±15% in accuracy and precision.
Concentrations were calculated using the following softwares: MDS Sciex Analyst software,
version 1.4.1. (Applied Biosystems/MDS Sciex, Ontario, Canada) and Thermo Electron
Corporation Watson LIMS software, version 7.0.0.01b (Inna Phase Corp., Philadelphia, PA,
USA).
The outcomes of interest for this analysis were the concentrations of betamethasone in the
maternal serum and in the cord blood. We also analyzed the ratio of maternal serum to cord
blood betamethasone concentrations. Univariate analysis was used to evaluate
betamethasone concentrations in ng/mL between singleton versus twin gestations and
between women with prepregnancy BMI <30 versus BMI ≥ 30. Continuous variables were
analyzed using the Wilcoxon Rank-Sum test for maternal data and Generalized Estimating
Equations (GEE), a regression model that can be used to adjust for correlated
observations[10], for infant data. Multivariable linear regression analysis was used to
examine the relationship between maternal serum betamethasone and obesity, plurality,
gestational age at delivery, number of steroid study courses, and time between the last
course of steroids and delivery. GEE regression models were used to examine the
relationship between cord blood betamethasone and these covariates. Log transformations of
betamethasone levels were used in the regression analyses. Nominal statistical significance
was set at a p-value less than 0.05.
RESULTS
There were 106 samples available for analysis (51 fetal [cord blood] and 55 maternal
[delivery blood]). Six of the 51 cord blood samples were insufficient to assess
betamethasone concentrations. Therefore, 45 cord blood and 55 maternal samples were
analyzed comparing maternal and cord blood concentrations in singleton to twin
pregnancies. All but 3 patients delivered secondary to spontaneous preterm labor with or
without intact membranes.
Forty-five neonates delivered within one week of betamethasone administration; 30 were
from singleton and 15 were from twin gestations. Of the 15, there were 6 twin pairs and 3
infants without samples from their co-twin. In the univariate analysis median maternal
serum betamethasone concentrations were similar for singleton (4.4 ng/mL, Interquartile
Range [IQR] 2.7, 6.7) compared to twin (5.2 ng/mL, IQR 3.1, 7.8) gestations, p=0.49.
Median cord blood betamethasone concentrations were higher in twin gestations, 4.4 ng/mL,
IQR 2.5, 8.2, compared to singletons, 1.4 ng/mL, IQR 1.0, 3.0, p=0.002. Mothers pregnant
with twins also received fewer courses of steroids than mothers of singletons, median 1 v. 3
courses, respectively, p=0.04. Figure 1 shows concentrations of betamethasone in cord blood
for singletons and twins by days from last course. Concentrations of betamethasone
decreased over time for both singletons and twins (p<0.0001). There was a trend towards an
increase in the ratio of maternal delivery blood to fetal cord in singletons compared to twins,
3.0±1.1 ng/mL v. 2.2±1.2 ng/mL; but, this finding was not statistically significant, p=0.07.
After controlling for the number of days since steroid administration, number of steroid
courses received, gestational age at delivery and maternal obesity, there were no differences
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in betamethasone concentrations in maternal serum or fetal cord blood between singletons
and twins (p=0.61 and p=0.14, respectively) (Table 1).
Of the 45 cord blood and 55 maternal samples available, 2 mothers with serum available
were missing information on BMI. Therefore, the second analysis evaluating the effect of
maternal obesity on betamethasone concentrations involved only 53 maternal samples.
Forty-one of those were non-obese (BMI<30) and 12 were obese (BMI≥30). Among the
obese group, 8 women had a BMI of <35, 2 had BMIs between 35 and 40, and 2 had BMIs
over 40. None of the women had a BMI over 50. Median maternal serum betamethasone
concentrations were 4.3 ng/mL, IQR 3.0, 6.1, and 5.0 ng/mL, IQR 2.7, 7.6, for non-obese
and obese women, p=0.74, respectively. In both groups, maternal betamethasone
concentrations (delivery blood values) decreased over time since last course (Figure 2). Cord
blood betamethasone concentrations were available for 43 neonates, from 35 non-obese and
8 obese mothers. These concentrations were also similar in both groups, 1.8 ng/mL, IQR
1.2, 4.6, versus 2.5 ng/mL, IQR 0.9, 6.5, p=0.82. The ratio of maternal serum to cord blood
betamethasone concentrations were also similar, 2.7±1.2 ng/mL in non-obese compared to
3.4±1.4 ng/mL in obese women, p=0.43. After controlling for the number of days since
steroid administration, number of steroid courses received, gestational age at delivery and
number of fetuses, there was not a significant association between maternal obesity and
maternal serum betamethasone p=0.67, or between maternal obesity and maternal cord
betamethasone concentrations, p=0.12 (Table 1). Additional regression analyses that
examined BMI as a continuous, rather than dichotomous, variable still did not demonstrate a
significant linear association between BMI and serum betamethasone concentration.
DISCUSSION
In this analysis we did not find a significant association between betamethasone levels and
either plurality or obesity, therefore the dosing used to achieve maternal or fetal serum levels
is not likely to explain the apparent inefficacy of betamethasone in decreasing RDS in twin
gestations. Ballabh et al., performed a similar study evaluating the pharmacokinetics of
betamethasone in singleton and twin pregnancies.[7] They found that the volume of
distribution of the drug was not different between singletons and twins, but there was a
shorter half-life (7.2 ± 2.4 versus 9.0 ± 2.7 hours; P < .017) and a trend towards a longer
clearance (8.4 ± 6.4 versus 5.7 ± 3.1 L/h; P = .06) in twins compared to singletons. In
contrast to our study, Ballabh and colleagues did not adjust for the number of days from
steroid administration to delivery, although they mention there was a wide variation in this
time period. They did not adjust for obesity, but mentioned that the maternal weights in the
singleton and twin group were similar. In contrast to their study, we could not measure half-
life because maternal serum was not collected serially. Another limitation to our study was
the small sample size which limits the interpretation of our results. Due to the small
numbers, we were also not able to evaluate more subtle effects of variables such as
gestational age or degrees of obesity on betamethasone concentrations.
Maximizing the benefits of antenatal corticosteroids is of particular importance since the
rate of preterm birth continues to rise. In 2007, the most recent year for which data are
available, the preterm birth rate in the United States was 12.7%; this is a 20% increase since
1990.[11] Twin pregnancies are at markedly increased risk of preterm delivery, and the
frequency of twins has also increased from 24.8 per 1000 live births in 1995 to 32.2 per
1000 in 2005.[12] Although antenatal corticosteroids are routinely administered to twin
gestations at risk for preterm delivery, the efficacy data are less robust than that of
singletons. A recent Cochrane meta-analysis performed by Roberts and Dalziel showed a
non-significant reduction in the rate of RDS in twins after administration of steroids, OR
0.85, 95% confidence interval 0.60 to 1.20, but this is based on 4 studies with 167 cases and
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153 controls.[6] Our findings suggest that the concentration of betamethasone achieved in
maternal serum and fetal cord blood from twin gestations is similar to that of singletons,
making betamethasone concentrations an unlikely explanation for the findings of Roberts
and Dalziel[6]. It is conceivable that a benefit may be demonstrated if a larger number of
twins could be evaluated.
The WHO has called the increasing prevalence of obesity an epidemic.[4] Although there is
a biologic plausibility to explain why antenatal corticosteroids may have altered efficacy in
obese patients, we are not aware of any prospective studies evaluating the rates of RDS in
offspring of obese women.
In conclusion we did not find that betamethasone concentrations in maternal or umbilical
cord blood were affected by singleton/twin gestation or by obesity. A prospective,
observational cohort study with larger numbers of patients would be ideal to validate our
findings and to provide further evidence supporting our conclusions.
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Betamethasone (Beta) level by days since steroid dose in cord blood in ng/mL in singleton
versus twin pregnancies
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Betamethasone (Beta) level by days since steroid dose in maternal serum in ng/mL in obese
versus non-obese pregnant women
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